Differential effect of amphetamine on c-fos expression in female aromatase knockout (ArKO) mice compared to wildtype controls

Psychoneuroendocrinology

Volumn 36, Issue 5, 2011, Pages 761-768

  Chavez, Carolina ^a,b,c   Gogos, Andrea ^a   Hill, Rachel ^a   Van Sinderen, Michelle ^b,d   Simpson, Evan ^d   Boon, Wah Chin ^a,b,d   Van den Buuse, Maarten ^a,c  

^a FLOREY INSTITUTE OF NEUROSCIENCE AND MENTAL HEALTH   (Australia)

^b MONASH UNIVERSITY   (Australia)

^c UNIVERSITY OF MELBOURNE   (Australia)

^d HUDSON INSTITUTE OF MEDICAL RESEARCH   (Australia)

Author keywords

Amphetamine; Aromatase; Estrogen; Fos; Mice; Ovariectomy

Indexed keywords

AMPHETAMINE; AROMATASE; ESTROGEN; PROTEIN C FOS;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BRAIN; CAUDATE NUCLEUS; CINGULATE GYRUS; CONTROLLED STUDY; FEMALE; MOUSE; NONHUMAN; NUCLEUS ACCUMBENS; OVARIECTOMY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PUTAMEN; WILD TYPE;

AMPHETAMINE; ANIMALS; AROMATASE; BODY WEIGHT; FEMALE; GENE EXPRESSION; GENES, FOS; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MODELS, BIOLOGICAL; OVARIECTOMY;

EID: 79955523984     PISSN: 03064530     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.psyneuen.2010.10.013     Document Type: Article

References (43)

1. Abraham G.E., Lobotsky J., Lloyd C.W. Metabolism of testosterone and androstenedione in normal and ovariectomized women. J. Clin. Invest. 1969, 48:696-703.
2. Bakker J., Honda S., Harada N., Balthazart J. The aromatase knockout (ArKO) mouse provides new evidence that estrogens are required for the development of the female brain. Ann. N. Y. Acad. Sci. 2003, 1007:251-262.
3. Balthazart J., Foidart A., Surlemont C., Harada N. Distribution of aromatase-immunoreactive cells in the mouse forebrain. Cell Tissue Res. 1991, 263:71-79.
4. Becker J.B., Cha J.H. Estrous cycle-dependent variation in amphetamine-induced behaviors and striatal dopamine release assessed with microdialysis. Behav. Brain Res. 1989, 35:117-125.
5. Becker J.B. Estrogen rapidly potentiates amphetamine-induced striatal dopamine release and rotational behavior during microdialysis. Neurosci. Lett. 1990, 118:169-171.
6. Becker J.B., Rudick C.N. Rapid effects of estrogen or progesterone on the amphetamine-induced increase in striatal dopamine are enhanced by estrogen priming: a microdialysis study. Pharmacol. Biochem. Behav. 1999, 64:53-57.
7. Bui H.N., Struys E.A., Martens F., de Ronde W., Thienpont L.M., Kenemans P., Verhoeven M.O., Jakobs C., Dijstelbloem H.M., Blankenstein M.A. Serum testosterone levels measured by isotope dilution-liquid chromatography-tandem mass spectrometry in postmenopausal women versus those in women who underwent bilateral oophorectomy. Ann. Clin. Biochem. 2010, 47:248-252.
8. Caruso D., Pesaresi M., Maschi O., Giatti S., Garcia-Segura L.M., Melcangi R.C. Effects of short- and long-term gonadectomy on neuroactive steroid levels in the central and peripheral nervous system of male and female rats. J. Neuroendocrinol. 2010, 22:1137-1147.
9. Castle D.J., Abel K., Takei N., Murray R.M. Gender differences in schizophrenia: hormonal effect or subtypes?. Schizophr. Bull. 1995, 21:1-12.
10. Castner S.A., Becker J.B. Sex differences in the effect of amphetamine on immediate early gene expression in the rat dorsal striatum. Brain Res. 1996, 712:245-257.
11. Chavez C., Gogos A., Jones M.E., Van den Buuse M. Psychotropic drug-induced locomotor hyperactivity and prepulse inhibition regulation in male and female aromatase knockout (ArKO) mice: role of dopamine D1 and D2 receptors and dopamine transporters. Psychopharmacology (Berl.) 2009, 206:267-279.
12. Conversi D., Bonito-Oliva A., Orsini C., Cabib S. Habituation to the test cage influences amphetamine-induced locomotion and Fos expression and increases FosB/DeltaFosB-like immunoreactivity in mice. Neuroscience 2006, 141:597-605.
13. Costa F.G., Frussa-Filho R., Canteras N.S., Valera A.G., Felicio L.F. Blockade of neurotensin receptors during amphetamine discontinuation indicates individual variability. Neuropeptides 2007, 41:83-91.
14. Curran T., Morgan J.I. Fos: an immediate-early transcription factor in neurons. J. Neurobiol. 1995, 26:403-412.
15. Ellem S.J., Risbridger G.P. Aromatase and prostate cancer. Minerva Endocrinol. 2006, 31:1-12.
16. Fisher C.R., Graves K.H., Parlow A.F., Simpson E.R. Characterization of mice deficient in aromatase (ArKO) because of targeted disruption of the cyp19 gene. Proc. Natl. Acad. Sci. U. S. A. 1998, 95:6965-6970.
17. Franklin K.B.J., Paxinos G. The Mouse Brain in Stereotaxic Coordinates 1996, Academic Press, San Diego.
18. Funk D., Li Z., Fletcher P.J., Le A.D. Effects of injections of 8-hydroxy-2-(di-n-propylamino)tetralin or muscimol in the median raphe nucleus on c-fos mRNA in the rat brain. Neuroscience 2005, 131:475-479.
19. Geyer M.A., Markou A. Animal models of psychiatric disorders. Psychopharmacology: The Fourth Generation of Progress 1995, 787-798. Raven Press, New York. F. Bloom, D. Kupfer (Eds.).
20. Gogos A., van den Buuse M. Estrogen and progesterone prevent disruption of prepulse inhibition by the serotonin-1A receptor agonist 8-OH-DPAT. J. Pharmacol. Exp. Ther. 2004, 309:267-274.
21. Gogos A., Kwek P., Chavez C.A., van den Buuse M. Estrogen treatment blocks 8-OH-DPAT- and apomorphine-induced disruptions of prepulse inhibition: involvement of dopamine D1 or D2, serotonin 5-HT1A, 5-HT2A or 5-HT7 receptors. J. Pharmacol. Exp. Ther. 2010, 333:218-227.
22. Häfner H., Behrens S., De Vry J., Gattaz W.F. Oestradiol enhances the vulnerability threshold for schizophrenia in women by an early effect on dopaminergic neurotransmission. Evidence from an epidemiological study and from animal experiments. Eur. Arch. Psychiatry Clin. Neurosci. 1991, 241:65-68.
23. Häfner H., an der Heiden W., Behrens S., Gattaz W.F., Hambrecht M., Loffler W., Maurer K., Munk-Jorgensen P., Nowotny B., Riecher-Rossler A., Stein A. Causes and consequences of the gender difference in age at onset of schizophrenia. Schizophr. Bull. 1998, 24:99-113.
24. Hewitt K.N., Pratis K., Jones M.E., Simpson E.R. Estrogen replacement reverses the hepatic steatosis phenotype in the male aromatase knockout mouse. Endocrinology 2004, 145:1842-1848.
25. Hill R.A., McInnes K.J., Gong E.C., Jones M.E., Simpson E.R., Boon W.C. Estrogen deficient male mice develop compulsive behavior. Biol. Psychiatry 2007, 61:359-366.
26. Hill R.A., Chua H.K., Jones M.E., Simpson E.R., Boon W.C. Estrogen deficiency results in apoptosis in the frontal cortex of adult female aromatase knockout mice. Mol. Cell. Neurosci. 2009, 41:1-7.
27. Ito T., Horton R. The source of plasma dihydrotestosterone in man. J. Clin. Invest. 1971, 50:1621-1627.
28. Jones M.E., McInnes K.J., Boon W.C., Simpson E.R. Estrogen and adiposity-utilizing models of aromatase deficiency to explore the relationship. J. Steroid. Biochem. Mol. Biol. 2007, 106:3-7.
29. Korse C.M., Bonfrer J.M., van Beurden M., Verheijen R.H., Rookus M.A. Estradiol and testosterone levels are lower after oophorectomy than after natural menopause. Tumour Biol. 2009, 30:37-42.
30. Kudwa A.E., Harada N., Honda S.I., Rissman E.F. Effects of organisational oestradiol on adult immunoreactive oestrogen receptors (α and β) in the male mouse brain. J. Neuroendocrinol. 2007, 19:767-772.
31. McPherson S.J., Wang H., Jones M.E., Pedersen J., Iismaa T.P., Wreford N., Simpson E.R., Risbridger G.P. Elevated androgens and prolactin in aromatase-deficient mice cause enlargement, but not malignancy, of the prostate gland. Endocrinology 2001, 142:2458-2467.
32. Milanovic D., Pesic V., Rakic L., Kanazir S., Ruzdijic S. Enhancement of AP-1 DNA-binding activity during amphetamine- and phencyclidine-mediated behaviour in rats. Neuropharmacology 2006, 50:924-933.
33. Miyaura C., Toda K., Inada M., Ohshiba T., Matsumoto C., Okada T., Ito M., Shizuta Y., Ito A. Sex- and age-related response to aromatase deficiency in bone. Biochem. Biophys. Res. Commun. 2001, 280:1062-1068.
34. Pierman S., Douhard Q., Balthazart J., Baum M.J., Bakker J. Attraction thresholds and sex discrimination of urinary odorants in male and female aromatase knockout (ArKO) mice. Horm. Behav. 2006, 49:96-104.
35. Pierman S., Douhard Q., Bakker J. Evidence for a role of early oestrogens in the central processing of sexually relevant olfactory cues in female mice. Eur. J. Neurosci. 2008, 27:423-431.
36. Rademacher D.J., Napier T.C., Meredith G.E. Context modulates the expression of conditioned motor sensitization, cellular activation and synaptophysin immunoreactivity. Eur. J. Neurosci. 2007, 26:2661-2668.
37. Sasahara K., Shikimi H., Haraguchi S., Sakamoto H., Honda S., Harada N., Tsutsui K. Mode of action and functional significance of estrogen-inducing dendritic growth, spinogenesis, and synaptogenesis in the developing Purkinje cell. J. Neurosci. 2007, 27:7408-7417.
38. Silverman J.L., Koenig J.I. Evidence for the involvement of ERβ and RGS9-2 in 17-β estradiol enhancement of amphetamine-induced place preference behavior. Horm. Behav. 2007, 52:146-155.
39. Simpson E.R. Models of aromatase insufficiency. Semin. Reprod. Med. 2004, 22:25-30.
40. Smith D.G., Qi H., Svenningsson P., Wade M., Davis R.J., Gehlert D.R., Nomikos G.G. Behavioral and biochemical responses to d-amphetamine in MCH1 receptor knockout mice. Synapse 2008, 62:128-136.
41. Taziaux M., Keller M., Bakker J., Balthazart J. Sexual behavior activity tracks rapid changes in brain estrogen concentrations. J. Neurosci. 2007, 27:6563-6572.
42. Trinh J.V., Nehrenberg D.L., Jacobsen J.P., Caron M.G., Wetsel W.C. Differential psychostimulant-induced activation of neural circuits in dopamine transporter knockout and wild type mice. Neuroscience 2003, 118:297-310.
43. Wong J., Weickert C.S. Transcriptional interaction of an estrogen receptor splice variant and ErbB4 suggests convergence in gene susceptibility pathways in schizophrenia. J. Biol. Chem. 2009, 284:18824-18832.